Cytokinetics (CYTK) is set up for stronger sales and potential stock gains as its new heart drug Myqorzo continues to build momentum, UBS Securities said Monday in a report.

Myqorzo treats obstructive hypertrophic cardiomyopathy, a condition where the heart muscle becomes too thick and restricts blood flow. Symptoms often include shortness of breath, chest pain, dizziness and fatigue. UBS said doctors in its survey were enthusiastic about using Myqorzo because of its safety profile and easier monitoring requirements compared with existing treatments.

The drug also recently succeeded in a late-stage study for non-obstructive HCM, a related form of the disease, and UBS said that could open a second wave of demand if approved, potentially starting in late 2027.

UBS expects Myqorzo to become a key product for Cytokinetics and forecasts peak annual sales of about $4 billion for obstructive HCM alone, with additional upside from non-obstructive HCM. Earnings updates may help support the stock as the launch progresses, the report said.

UBS raised its rating on Cytokinetics stock to buy from neutral and increased its price target to $115 from $69.

Price: 85.46, Change: +3.27, Percent Change: +3.97